加载中
NYSEReal EstateReal Estate - Services
最新数据
US$1.575
−US$0.025 · -1.56%
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
常规交易时段
US$1.575
−US$0.025 · -1.56%
盘中时间采用ET。市场数据可能有所延迟。
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
日内区间
当前US$1.575
52周区间
当前US$1.575
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
53
合理估值
情绪
60
多空交织
风险
62
高风险
动量
72
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
日内区间
当前US$1.575
52周区间
当前US$1.575
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 91.7万 USD | 63.7万 USD | 27.9万 USD | 41万 USD | 80.2万 USD |
| 销货成本 | 42.2万 USD | 15.4万 USD | — | — | 7万 USD |
| 毛利 | 49.5万 USD | 48.3万 USD | 27.9万 USD | 41万 USD | 80.2万 USD |
| 研究与开发 | 1282.3万 USD | 9403.1万 USD | 631.2万 USD | 874.2万 USD | 490.7万 USD |
| 销售、一般及管理费用 | 1378.1万 USD | 885.4万 USD | 893.2万 USD | 1697.8万 USD | 2041.6万 USD |
| 营业费用 | 2660.4万 USD | 1.03亿 USD | 1532.2万 USD | 6088.7万 USD | 2900.1万 USD |
| 利息收入 | 199.6万 USD | 238.3万 USD | 325.3万 USD | 20.1万 USD | 2000 USD |
| 利息支出 | 65.8万 USD | 24.8万 USD | — | 6000 USD | 1.2万 USD |
| 折旧和摊销 | 28.8万 USD | 22.5万 USD | 7.8万 USD | 7.2万 USD | 7万 USD |
| 营业利润 | −2610.9万 USD | −1.03亿 USD | −1504.3万 USD | −6047.7万 USD | −2119.9万 USD |
| 净利润 | −3052万 USD | −3441万 USD | −187.6万 USD | −1.25亿 USD | −2454.4万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI250.74万0.00%2.3万亿 USD0.03%US$381.86-0.02%
Vanguard Extended Market ETFVXF121.93万0.00%954亿 USD0.05%US$234.51-0.21%
iShares Micro-Cap ETFIWC16.72万0.01%13.17亿 USD0.60%US$182.61-0.21%
U.S. Micro Cap Portfolio ETFDFMC13.72万0.00%75.58亿 USD0.43%US$57.79-0.04%
Dimensional - US Small Cap ETFDFAS6.63万0.00%338.69亿 USD0.31%US$78.49+0.18%
Dimensional - US Core Equity 2 ETFDFAC5.39万0.00%885.96亿 USD0.21%US$45.385+0.12%
U.S. Vector Equity Portfolio ETF Class SharesDXUV3.55万0.00%61.81亿 USD0.26%US$68.3771+0.14%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR2.92万0.00%455.91亿 USD0.17%US$84.435-0.01%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASDimensional - US Core Equity 2 ETFDFACU.S. Vector Equity Portfolio ETF Class SharesDXUVU.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
